Research ExplorerPublicationsOne-Year Course of Periprocedural Anticoagulation in Atrial ...

One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey

Standard

One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. / Bejinariu, Alexandru Gabriel; Makimoto, Hisaki; Wakili, Reza; Mathew, Shibu; Kosiuk, Jedrzej; Linz, Dominik; Steinfurt, Johannes; Dechering, Dirk G; Meyer, Christian; Veltmann, Christian; Kelm, Malte; Frommeyer, Gerrit; Eckardt, Lars; Deneke, Thomas; Duncker, David; Müller, Patrick.

In: CARDIOLOGY, Vol. 145, No. 10, 01.10.2020, p. 676-681.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bejinariu, AG, Makimoto, H, Wakili, R, Mathew, S, Kosiuk, J, Linz, D, Steinfurt, J, Dechering, DG, Meyer, C, Veltmann, C, Kelm, M, Frommeyer, G, Eckardt, L, Deneke, T, Duncker, D & Müller, P 2020, 'One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey', CARDIOLOGY, vol. 145, no. 10, pp. 676-681. https://doi.org/10.1159/000509399

APA

Bejinariu, A. G., Makimoto, H., Wakili, R., Mathew, S., Kosiuk, J., Linz, D., Steinfurt, J., Dechering, D. G., Meyer, C., Veltmann, C., Kelm, M., Frommeyer, G., Eckardt, L., Deneke, T., Duncker, D., & Müller, P. (2020). One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. CARDIOLOGY, 145(10), 676-681. https://doi.org/10.1159/000509399

Vancouver

Bejinariu AG, Makimoto H, Wakili R, Mathew S, Kosiuk J, Linz D et al. One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey. CARDIOLOGY. 2020 Oct 1;145(10):676-681. https://doi.org/10.1159/000509399

Bibtex

@article{c283732fd859404b9e075b908a3be7b2,
title = "One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey",
abstract = "INTRODUCTION: Periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation procedures are changing rapidly.OBJECTIVE: To assess the management and course of periprocedural OAC for AF ablation procedures in experienced electrophysiology (EP) centers in Germany over the last 12 months.METHODS: The data are based on an electronic questionnaire, which was sent to 35 experienced EP centers in September 2018 and then exactly 1 year later. Participants provided information on their periprocedural OAC management, the handling with dual therapy (OAC plus single antiplatelet therapy), the availability of specific antidotes, the transseptal puncture approach, and noteworthy complications.RESULTS: Responses were received from all 35 centers and represent 10,010 AF ablation procedures annually. In 2018, the administration of vitamin K antagonist (VKA) was continued throughout the procedure at all centers (100%). In contrast, the majority of centers used minimally interrupted periprocedural non-vitamin K antagonist oral anticoagulants (NOAC) (54.3%), 13 centers (37.2%) completely interrupted NOAC, and only 3 centers (8.5%) continued NOAC throughout the procedure. At the 1-year follow-up survey, 32 centers were found to have continued their previous strategy of periprocedural OAC and 3 changed from a minimally interrupted to a continued NOAC strategy. Of note, 30 centers (85.7%) performed transseptal puncture fluoroscopically without additional cardiac imaging. In the setting of uninterrupted periprocedural OAC management, no relevant complications were noted.CONCLUSION: Our survey shows marked heterogeneous periprocedural OAC management at experienced EP centers in Germany. Whereas continuation of VKA has already been integrated into clinical practice, the majority of centers still use a minimally interrupted NOAC strategy.",
keywords = "Administration, Oral, Anticoagulants/therapeutic use, Atrial Fibrillation/drug therapy, Catheter Ablation, Germany, Heparin, Low-Molecular-Weight, Humans, Stroke/drug therapy, Surveys and Questionnaires",
author = "Bejinariu, {Alexandru Gabriel} and Hisaki Makimoto and Reza Wakili and Shibu Mathew and Jedrzej Kosiuk and Dominik Linz and Johannes Steinfurt and Dechering, {Dirk G} and Christian Meyer and Christian Veltmann and Malte Kelm and Gerrit Frommeyer and Lars Eckardt and Thomas Deneke and David Duncker and Patrick M{\"u}ller",
note = "{\textcopyright} 2020 The Author(s) Published by S. Karger AG, Basel.",
year = "2020",
month = oct,
day = "1",
doi = "10.1159/000509399",
language = "English",
volume = "145",
pages = "676--681",
journal = "CARDIOLOGY",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "10",

}

RIS

TY - JOUR

T1 - One-Year Course of Periprocedural Anticoagulation in Atrial Fibrillation Ablation: Results of a German Nationwide Survey

AU - Bejinariu, Alexandru Gabriel

AU - Makimoto, Hisaki

AU - Wakili, Reza

AU - Mathew, Shibu

AU - Kosiuk, Jedrzej

AU - Linz, Dominik

AU - Steinfurt, Johannes

AU - Dechering, Dirk G

AU - Meyer, Christian

AU - Veltmann, Christian

AU - Kelm, Malte

AU - Frommeyer, Gerrit

AU - Eckardt, Lars

AU - Deneke, Thomas

AU - Duncker, David

AU - Müller, Patrick

N1 - © 2020 The Author(s) Published by S. Karger AG, Basel.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - INTRODUCTION: Periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation procedures are changing rapidly.OBJECTIVE: To assess the management and course of periprocedural OAC for AF ablation procedures in experienced electrophysiology (EP) centers in Germany over the last 12 months.METHODS: The data are based on an electronic questionnaire, which was sent to 35 experienced EP centers in September 2018 and then exactly 1 year later. Participants provided information on their periprocedural OAC management, the handling with dual therapy (OAC plus single antiplatelet therapy), the availability of specific antidotes, the transseptal puncture approach, and noteworthy complications.RESULTS: Responses were received from all 35 centers and represent 10,010 AF ablation procedures annually. In 2018, the administration of vitamin K antagonist (VKA) was continued throughout the procedure at all centers (100%). In contrast, the majority of centers used minimally interrupted periprocedural non-vitamin K antagonist oral anticoagulants (NOAC) (54.3%), 13 centers (37.2%) completely interrupted NOAC, and only 3 centers (8.5%) continued NOAC throughout the procedure. At the 1-year follow-up survey, 32 centers were found to have continued their previous strategy of periprocedural OAC and 3 changed from a minimally interrupted to a continued NOAC strategy. Of note, 30 centers (85.7%) performed transseptal puncture fluoroscopically without additional cardiac imaging. In the setting of uninterrupted periprocedural OAC management, no relevant complications were noted.CONCLUSION: Our survey shows marked heterogeneous periprocedural OAC management at experienced EP centers in Germany. Whereas continuation of VKA has already been integrated into clinical practice, the majority of centers still use a minimally interrupted NOAC strategy.

AB - INTRODUCTION: Periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation procedures are changing rapidly.OBJECTIVE: To assess the management and course of periprocedural OAC for AF ablation procedures in experienced electrophysiology (EP) centers in Germany over the last 12 months.METHODS: The data are based on an electronic questionnaire, which was sent to 35 experienced EP centers in September 2018 and then exactly 1 year later. Participants provided information on their periprocedural OAC management, the handling with dual therapy (OAC plus single antiplatelet therapy), the availability of specific antidotes, the transseptal puncture approach, and noteworthy complications.RESULTS: Responses were received from all 35 centers and represent 10,010 AF ablation procedures annually. In 2018, the administration of vitamin K antagonist (VKA) was continued throughout the procedure at all centers (100%). In contrast, the majority of centers used minimally interrupted periprocedural non-vitamin K antagonist oral anticoagulants (NOAC) (54.3%), 13 centers (37.2%) completely interrupted NOAC, and only 3 centers (8.5%) continued NOAC throughout the procedure. At the 1-year follow-up survey, 32 centers were found to have continued their previous strategy of periprocedural OAC and 3 changed from a minimally interrupted to a continued NOAC strategy. Of note, 30 centers (85.7%) performed transseptal puncture fluoroscopically without additional cardiac imaging. In the setting of uninterrupted periprocedural OAC management, no relevant complications were noted.CONCLUSION: Our survey shows marked heterogeneous periprocedural OAC management at experienced EP centers in Germany. Whereas continuation of VKA has already been integrated into clinical practice, the majority of centers still use a minimally interrupted NOAC strategy.

KW - Administration, Oral

KW - Anticoagulants/therapeutic use

KW - Atrial Fibrillation/drug therapy

KW - Catheter Ablation

KW - Germany

KW - Heparin, Low-Molecular-Weight

KW - Humans

KW - Stroke/drug therapy

KW - Surveys and Questionnaires

U2 - 10.1159/000509399

DO - 10.1159/000509399

M3 - SCORING: Journal article

C2 - 32854099

VL - 145

SP - 676

EP - 681

JO - CARDIOLOGY

JF - CARDIOLOGY

SN - 0008-6312

IS - 10

ER -